Tag: GlobeNewswire

– Completes planned leadership transition as Prenetics revenue is almost entirely IM8

– Prenetics’ finance leadership function now based in the United States

– The Company will report third quarter 2026 results on November 18, 2026, and host a live-streamed earnings event on Stocktwits the same day at 8:30 a.m. Eastern Time, during which management will discuss the results and hold a Q&A session.

– The live-stream will be accessible at https://stocktwits.com/symbol/PRE. Investors who wish to submit questions may do so by emailing investors@prenetics.com.

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) — Prenetics Global Limited (Nasdaq: PRE) (“Prenetics” or the “Company”), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced that Brian J. Rosin will succeed Stephen Lo as Chief Financial Officer of Prenetics, effective December 31, 2026. The Company’s Board of Directors is expected to formalize the appointment at its meeting on November 12, 2026. Mr. Rosin, who joined as Chief Financial Officer of IM8 in May 2026, will serve as Chief Financial Officer-designate of Prenetics through year-end, continuing as Chief Financial Officer of IM8 and working alongside Mr. Lo, and will then lead the Company’s global finance organization and continue to report to Chief Executive Officer Danny Yeung.

The appointment will complete a transition the Company planned when Mr. Rosin joined: that he would first build a deep understanding of the business before assuming the group CFO role. With IM8 now representing substantially all of Prenetics’ revenue, the Company will operate with a single Chief Financial Officer, and no separate IM8 CFO role will be filled.

Since joining, Mr. Rosin has co-led the Company’s quarterly earnings presentations, helped secure the $1 billion growth commitment financing from General Catalyst’s Customer Value Fund, and played a central role in broadening the Company’s engagement with U.S. investors and sell-side research analysts. Based in the United States, he will strengthen the Company’s presence in its largest market and its primary capital market.

Mr. Rosin’s appointment caps a deliberate build-out of the Company’s finance leadership in the United States. As part of that build-out, Cindy Tat joined the Company in August, 2026 as Vice President, Financial Controller. Ms. Tat, a U.S.-based certified public accountant, brings more than 16 years of SEC reporting and SOX compliance experience, having previously served as Vice President, Controller of Nasdaq-listed WM Technology and of Iteris. With its finance leadership function now based in the United States, the Company is aligning its finance and reporting infrastructure with its U.S. operations.

As previously announced, Stephen Lo will continue to serve as Chief Financial Officer through December 30, 2026, working closely with Mr. Rosin to ensure an orderly transition. Following the transition, Mr. Lo will remain with the Company as a Senior Advisor.

Danny Yeung, Co-Founder and Chief Executive Officer of Prenetics, commented: “When Brian joined us in May, the plan was for him to learn IM8 from the inside and then lead finance for the whole company. He has done exactly that. Prenetics today is IM8, and one CFO with Brian’s background in high-growth consumer health is the right structure for where we are going. The United States is IM8’s largest market and our primary capital market, so that is where our finance leadership needs to sit: close to our customers, our investors and the analysts who cover us. With Brian and Cindy leading a U.S.-based finance team, we are building the reporting and controls infrastructure to match the scale we are growing into. I also want to thank Stephen for eight years of dedication and for his partnership through our transformation.”

Stephen Lo, Chief Financial Officer of Prenetics, commented: “Being part of Prenetics’ journey over the past eight years, from our early days to the transformation into IM8, has been a privilege. I’m leaving at a time when the business has never had more momentum, and I’m certain that under Danny’s leadership IM8 will keep reaching new heights and bringing new innovations to customers around the world. I’ve worked closely with Brian since he joined, and I have full confidence in him to lead finance for the Company. I look forward to supporting a seamless transition through year-end, and to continuing to support the team as a Senior Advisor.”

Brian J. Rosin, Chief Financial Officer-designate of Prenetics, commented: “Over the past six months I’ve had the chance to work inside IM8 every day, from our customer economics to the financing that funds our growth — and what we’re building is rare: a global brand compounding at this pace, this early in its life. Prenetics today is IM8. With Cindy and our finance leadership team now based in the United States, our largest market, my focus as CFO will be simple: disciplined capital allocation, a clear path to sustained profitability, and consistent, transparent communication with our shareholders. I’m grateful to Danny and the Board for their confidence, and to Stephen for his partnership through this transition.”

Mr. Rosin brings nearly two decades of finance leadership in premium consumer health and e-Commerce. He previously served as Chief Financial Officer and Senior Vice President, e-Commerce Operations, of Wellbeam Consumer Health, and earlier held CFO roles at TruSkin, NATURELO Premium Supplements and Rant, Inc.

Third Quarter 2026 Results and Live-Stream Event
Prenetics will report its third quarter 2026 financial results on Wednesday, November 18, 2026, and will host a live-stream earnings event on Stocktwits at 8:30 a.m. Eastern Time, in the same format as its second quarter event. Mr. Yeung and Mr. Rosin, will review the results and take questions. The live-stream will be accessible at https://stocktwits.com/symbol/PRE. Investors who wish to submit questions may do so by emailing investors@prenetics.com.

About Prenetics
Prenetics Global Limited (Nasdaq: PRE) is a leading consumer health company on a mission to advance human health and longevity. Its flagship brand, IM8, co-founded with David Beckham, is redefining premium daily nutrition through science-backed formulations — anchored by Daily Ultimate Essentials, a 90-ingredient daily nutrition system that is NSF Certified for Sport and clinically studied. IM8 is the fastest-growing premium supplement brand ever recorded, reaching approximately $251 million in annualized run-rate revenue within 20 months of launch, shipping to 46 countries, and delivering well over 200,000 servings daily. IM8’s ambassador and equity-partner roster includes David Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman, Jay Shetty, Inter Miami CF and the NBA. Learn more at prenetics.com and im8health.com.

About IM8
IM8 is a premium health and longevity brand co-founded by David Beckham and built with an elite team of scientists spanning medicine, academia and space science. Its flagship product, Daily Ultimate Essentials, delivers 90 ingredients in a single daily sachet – engineered to replace 16 different supplements in one drink – and is NSF Certified for Sport, non-GMO, vegan, free from common allergens and contains no artificial flavors, colors or sweeteners. Launched in December 2024, IM8 ships to 46 countries and has delivered more than 70 million servings. The brand is backed by a roster of global partners and ambassadors including Giannis Antetokounmpo, Aryna Sabalenka, Lily Collins, Jay Shetty, Ollie Bearman, Inter Miami CF and the NBA. IM8 is a wholly owned subsidiary of Prenetics Global Limited (Nasdaq: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more, visit www.IM8health.com.

Investor Relations Contact
investors@prenetics.com
PRE@mzgroup.us

Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com

Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about Prenetics Global Limited’s (the “Company”) goals, targets, projections, outlooks, beliefs, expectations, strategy, plans, objectives of management for future operations of the Company, and growth opportunities are forward-looking statements. Our guidance reflects management’s current estimates and assumptions as of the date of this press release, is subject to significant risks and uncertainties, and is not a guarantee of future performance. Actual results may differ materially. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” “guidance,” “outlook,” “forecast,” or other similar expressions. Forward-looking statements are based upon estimates and forecasts and reflect the views, assumptions, expectations, and opinions of the Company, which involve inherent risks and uncertainties, and therefore they should not be relied upon as being necessarily indicative of future results. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to: the Company may not be able to maintain and enhance its IM8 business and brand if it suffers negative publicity or fails to maintain a strong base of engaged customers and content creators, or otherwise fails to meet customers’ expectations; the Company’s ability to further develop and grow its business, including new products and services; and the Company’s ability to efficiently and effectively deploy financial and management resources towards maintaining and growing the business. In addition to the foregoing factors, you should also carefully consider the other risks and uncertainties described in the “Risk Factors” section of the Company’s most recent registration statement and the prospectus therein, and the other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. Unless otherwise specified, all information provided in this press release is as of the date of this press release, and the Company does not undertake any duty to update such information, except as required under applicable law. Nothing in this press release constitutes an offer to sell, or the solicitation of an offer to buy, any securities of the Company.

Etime system commits to at least $4 million a month in prepaid wireless purchase volume, with the initial rollout currently underway

BARTLETT, Tenn., Nov. 03, 2026 (GLOBE NEWSWIRE) — SurgePays, Inc. (NASDAQ: SURG) (“SurgePays” or the “Company”), a fintech company that launches and runs wireless brands, today announced a prepaid wireless agreement (the “Agreement”) with Zulie Venture Inc. dba Etime system (“Etime system”), a payments network serving more than 1,000 retail locations nationwide. Etime system has committed to buy at least $48 million in prepaid wireless airtime, top-up and refill transactions from SurgePays over the initial term of the Agreement from October 1, 2026 through September 30, 2027, with a minimum of $4 million a month. These amounts represent prepaid wireless purchase volume. The Agreement renews automatically each year at the same minimum commitment.

This Agreement generates new volume for SurgePays POS and began operating in early October.

“Retail payment networks run on reliability, and Etime system put a $4 million monthly minimum in writing because our platform delivers it,” said Brian Cox, Chief Executive Officer of SurgePays. “The new volume from this agreement is already running, and every month adds transactions to infrastructure we have already built. That is exactly how we intend to grow value for SurgePays.”

“Our merchants need reliable access to prepaid wireless products and fast transaction processing,” said Parvez Jasani, Founder and CEO of Zulie Venture Inc. “We are pleased to partner with SurgePays to support our merchants and their customers.   This agreement reflects our confidence in the partnership and our commitment to growing our prepaid wireless business.”

The agreement strengthens SurgePays POS, the Company’s retail sales and payments business at neighborhood stores.

About SurgePays, Inc.

SurgePays, Inc. (NASDAQ: SURG) is a fintech company that launches and runs wireless brands. Through its GrowthLine platform, SurgePays provides partners with carrier access, technology, payments, customer care, compliance and daily operations from platforms it developed and an operations center and NOC it runs. The Company also owns LinkUp Mobile, its own prepaid wireless brand, and operates SurgePays POS, which handles retail sales and payments for wireless companies at neighborhood stores. SurgePays brings affordable wireless service and prepaid financial products to consumers through partners and neighborhood stores. For more information, please visit www.surgepays.com.

About Zulie Venture Inc. dba Etime system

Zulie Venture Inc., doing business as Etime system and also operating the CellPay brand, is a Stafford, Texas-based payments platform founded in 2016, serving more than 1,000 retail merchant locations nationwide with prepaid wireless, bill payment, gift card and prepaid card products. CellPay ranked No. 5 overall on the 2020 Inc. 5000 with 25,358% three-year revenue growth and has processed more than $1 billion in lifetime transaction volume for nearly six million consumers. Learn more at cellpay.net.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the agreement between SurgePays and Etime system, the amount and timing of prepaid wireless transactions expected under the agreement, its renewal and the future performance of the Company. These statements are based on current expectations and assumptions that are subject to risks and uncertainties, and actual results could differ materially from those expressed or implied. There can be no assurance that Etime system will meet its committed monthly or annual volume, result in recurring volume, or that the agreement will renew. Prepaid wireless top-up volume represents the total value of transactions processed, and the net revenue and gross profit the Company recognizes from that volume may be significantly lower than the volume amounts described in this release. Factors that could cause actual results to differ materially include, among others, the Company’s dependence on carrier and payment relationships, partner performance, regulatory developments affecting wireless and payment services, competition, and the risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. SurgePays undertakes no obligation to update or revise any forward-looking statements, except as required by law.

Investor Relations Contact

SurgePays, Inc.

ir@surgepays.com

Partnership opens a new commerce channel, starting with approximately 20 million LG Smart TVs in the U.S.; restaurants to be the first category of focus

SANTA CLARA, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — SoundHound AI, Inc. (Nasdaq: SOUN), a global leader in voice and agentic AI, today announced a strategic partnership with LG Electronics to expand restaurant and merchant participation on LG Smart TVs in the United States. The collaboration lays the groundwork for a new commerce channel in the living room.

The partnership gives participating businesses a new way to reach customers in the home, with an initial footprint of approximately 20 million LG Smart TVs in the U.S. Restaurants will be the first category of focus, with plans to extend to retail and other merchant categories over time.

SoundHound is working with restaurant brands interested in participating as the ecosystem develops. Its platform already serves leading brands across thousands of locations, including Jersey Mike’s, Five Guys, and White Castle.

A New Frontier for Living Room Commerce

This initiative sets the stage for the living room TV to become a transaction channel for restaurant operators and merchants, and for a better overall commerce experience for the consumers they serve. It builds on SoundHound’s merchant network, which handles transaction routing and secure checkout.

For SoundHound, the partnership expands on the commercial channel it debuted at CES 2025. Over time, the company plans to broaden the commerce experiences it supports, bringing its roster of brands from across hospitality, travel, entertainment, banking and more to the smart devices it powers.

“The TV is the largest screen in the most social setting of every home, which makes it a highly untapped opportunity for commerce,” said Keyvan Mohajer, CEO and Co-Founder of SoundHound AI. “This partnership with LG lays the foundation for how brands can engage with audiences in the living room. By bringing commerce to smart screens, we see an opportunity to create an entirely new channel for merchants.”

Value for Restaurant & Retail Partners

For national quick service restaurant chains, local restaurant groups, and retail brands, commerce on the living room TV represents a way to reach customers where they spend their time.

SoundHound’s approach is designed to offer:

• Direct Customer Engagement: A new way to engage households, starting with approximately 20 million LG Smart TVs in the U.S., during peak dining and viewing windows.
• Zero Additional Hardware: Requires no new in-store hardware for participating restaurants.
• Seamless Integration: Integrates directly with the Point of Sale (POS) and kitchen execution systems restaurants already use.

SoundHound currently works with over 15,000 restaurant locations across the U.S. The company invites restaurant brands, national food chains, and retail partners to learn more about participating by visiting: www.soundhound.com/join-lg-electronics-smart-tv-commerce-ecosystem

About SoundHound AI
SoundHound AI (Nasdaq:SOUN) is a voice and agentic AI company that enables businesses to deliver natural, end-to-end conversational experiences across digital and physical channels, including phones, kiosks, chat, smart devices, drive-thrus, TVs, in-vehicle, and more. Its agentic platform, OASYS, is a self-learning, orchestrated AI system where organizations can build and deploy conversational AI agents to handle transactions, tasks, and workflows on behalf of customers and employees. Built on proprietary technology backed by 750+ patents and years of AI research, SoundHound serves leading brands across industries including automotive, financial services, healthcare, retail, telecommunications, and more. It powers millions of products and processes billions of interactions annually for enterprise customers worldwide. Learn more at: www.soundhound.com

Media:
Fiona McEvoy
415-610-6590
PR@SoundHound.com

Hofseth BioCare ASA (“HBC”) announces that its US spin-out AecorBio Inc. (“AecorBio”) has appointed Prof. Karl G. Sylvester, M.D., as Co-Founder and Consulting Chief Medical Officer. Dr. Sylvester is Professor of Surgery at Stanford University School of Medicine and has advised AecorBio on the clinical strategy for FT-002a-O since 2025.

In connection with Dr. Sylvester’s appointment at AecorBio, he has been granted share options for 972,491 shares of AecorBio’s Class C Common Stock, corresponding to approximately 9% of the currently outstanding shares in AecorBio. If these share options are exercised, the delivery of the shares is currently intended to be handled through a surrender of a corresponding number of shares of Class C Common Stock held by HBC. Together with previously granted share options, Dr. Sylvester will hold share options in AecorBio for 1,047,491 shares.

AecorBio’s full announcement, including an update on the FT-002a-O development programme, is available at https://aecorbio.com/#news/sylvester-cmo

For further information, please contact:
Dr. Crawford Currie, Head of Medical R&D at Hofseth BioCare ASA
Phone: +44 7968 195 497
E-mail: cc@hofsethbiocare.no

James Berger, Chief Commercial Officer at Hofseth BioCare ASA
Phone: +41 79 950 1034
E-mail: jb@hofsethbiocare.no

About Hofseth BioCare ASA:
Hofseth BioCare is a Norwegian consumer and pet health company founded on the core values of sustainability, optimal utilization of natural resources and full traceability. It upcycles the side streams of the salmon industry, taking fresh filleted salmon and converting it from a waste product into ingredients to improve human and pet health. These ingredients are ProGo®, a mix of bioactive peptides and collagen; OmeGo®, a whole salmon oil containing all the fatty acid fractions found in fish; and CalGo®/NT-II® salmon bone powder containing calcium hydroxyapatite and undenatured collagen for bone and joint health. HBC places scientific evidence at the forefront, which has led to important academic partnerships and the identification of unique health benefits. HBC is listed on Oslo Stock Exchange with ticker “HBC”.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to Article 17 of MAR and Section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Jon Olav Ødegård, CEO, on the time and date provided.

The New Energy Group EPSO-G (company code 302826889, registered office at Laisvės pr. 10, Vilnius, Lithuania) has announced the selection of board members for the new term of the Group company Tetas. Candidates are invited to submit their documents by 3 December 2026 inclusive.

The selection will seek two independent board members with competencies in commercial and contracting operations management. The members nominated by EPSO-G will be selected for the areas of financial management and control, project management, and organisational development and operational efficiency.

The board of Tetas, an energy infrastructure development and maintenance company, consists of five members elected for a four-year term. The term of the current board will end on 21 March 2027.

To ensure good governance and proper representation of the shareholder, the board will include two independent board members and three board members nominated by the parent company EPSO-G. The combination of different competencies will enable the board to assess the company’s operational decisions comprehensively and oversee their implementation.

The selection of independent board members is conducted by a five-member Selection Committee, consisting of three representatives of EPSO-G, one representative of the Ministry of Energy and one representative of the Governance Coordination Centre. The executive search agency J. Friisberg & Partners has been engaged for the selection. The Committee will submit recommendations on the selected candidates to the General Meeting of Shareholders.

The selection procedures for board members nominated by EPSO-G are carried out, and recommendations to the General Meeting of Shareholders are submitted, by the EPSO-G Remuneration and Nomination Committee.

The requirements for candidates and the application procedure can be found here: https://epsog.lt/wp-content/uploads/2026/11/TETAS-valdybos-nariu-atrankos-skelbimas_2026-11-03.pdf

The EPSO-G group of companies consists of the management company EPSO-G and six directly controlled companies: Amber Grid, Baltpool, Energy cells, EPSO-G Invest, Litgrid and Tetas. EPSO-G and its Group companies also hold shares in Rheinmetall Defence Lietuva, Baltic RCC OÜ and TSO Holding AS. The rights and obligations of the sole shareholder of EPSO-G are exercised by the Ministry of Energy of the Republic of Lithuania.

Considering that during the shares buy-back process of INVL Technology (hereinafter – “the Company”), the Company acquired 543,571 shares for EUR 2,999,859.61 from the Company’s shareholders for which they were paid on 30 October 2026, the Company announces the data on shares issued by the Company as of 30 October 2026:

Type of shares	Number of shares and total voting rights granted by the issued shares, units	Number of votes for the quorum of the General Shareholders Meeting, units	Nominal value, EUR	Total nominal value and authorized capital, EUR	Portion of the authorized capital, %
Ordinary registered shares	12,175,321	11,434,829	0.29	3,530,843.09	100

The person authorized to provide additional information: 
INVL Technology Managing Partner 
Kazimieras Tonkūnas 
E-mail  k.tonkunas@invltechnology.lt

New Energy Group EPSO-G (legal entity code 302826889, registered office address Laisvės pr. 10, Vilnius, Lithuania)

EPSO-G Invest, the EPSO-G group’s company managing investments in the defence industry, announces a public selection process for the position of CEO. Applications for this position may be submitted until 03-12-2026 inclusive.

In line with the highest standards of transparency and good governance practices, representatives of both shareholders of EPSO-G Invest will participate in the candidate selection process: the EPSO-G Remuneration and Nomination Committee, in which independent members form the majority, and a representative of Valstybės investicinis kapitalas. The selection process will be conducted by the recruitment agency AIMS International Lietuva.

Once the selection procedures have been completed and the candidates have been vetted in accordance with the requirements of the Law on the Protection of Objects of Importance to Ensuring National Security and the Law on the Prevention of Corruption, the decision on the appointment of the CEO from among the selected candidates will be made by the general meeting of shareholders of EPSO-G Invest.

EPSO-G Invest is a company of the new energy group EPSO-G, 51% of whose shares are held by EPSO-G and the remaining 49% by Valstybės investicinis kapitalas.

The requirements for candidates and the application procedure can be found here: EPSO-G-Invest-vadoves-o-skelbimas_2026-11-03.pdf

The EPSO-G group of companies consists of the holding company EPSO-G and its six direct subsidiaries Amber Grid, Baltpool, Energy cells, EPSO-G Invest, Litgrid and Tetas. EPSO-G and its Group companies also hold shares in Rheinmetall Defence Lietuva, Baltic RCC OÜ and TSO Holding AS. The rights and obligations of the sole shareholder of EPSO-G are exercised by the Ministry of Energy of the Republic of Lithuania.

The retail turnover (including VAT) of the Apranga Group amounted to EUR 36.1 million in October 2026 and increased by 4.1% compared to October 2025.

The retail turnover (including VAT) of Apranga Group reached EUR 326.9 million in January-October 2026 and increased by 8.8% compared to the corresponding period of 2025.

In January-October 2026, the retail turnover of Apranga Group in Lithuania increased by 10.6% year-to-year, in Latvia increased by 5.9% and increased by 6.4% in Estonia.

Currently Apranga Group operates the chain of 174 stores (103 in Lithuania, 44 in Latvia, and 27 in Estonia) with a total area of 93.7 thousand sq. m., or by 1.1% more than a year ago.

Rimantas Perveneckas
„Apranga“ Group General Manager
+370 5 2390801

– Company to Host Conference Call on November 10, 2026, at 4:30 p.m. ET –

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2026, after the market close on Tuesday, November 10, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day.

Title:	Capricor Therapeutics Third Quarter 2026 Financial Results and Recent Corporate Update Conference Call and Webcast
Date:	Tuesday, November 10, 2026
Time:	4:30 p.m. ET
Call Details:	Toll-Free: 1-800-717-1738
	International: 1-646-307-1865
	Conference ID: 13662
	Participants may dial in using the numbers above and ask to be joined to the call, or use the Call me™ link for instant telephone access to the event.
Webcast:	Click here

A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company’s website at www.capricor.com.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for the treatment of Duchenne muscular dystrophy (DMD), evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com and follow Capricor on Facebook, Instagram and X.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful, which would delay or prevent product approval; revenue and reimbursement estimates; projected terms of definitive agreements, our financial position, our possible uses of existing cash and investment resources; results of securities litigation; and statements regarding our litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize Deramiocel independent of our existing distribution agreement and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as filed with the Securities and Exchange Commission on August 14, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

Deramiocel and Capricor’s StealthX™ exosome therapeutics are investigational and have not been approved for commercial use in any indication.

For more information, please contact:

Capricor Media Contact:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
ckasunich@kcsa.com / rcona@kcsa.com
212.896.1241 / 516.779.2630

Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755

Following a court-supervised restoration, NUGS plans to combine with Scopien, a sovereign AI platform

LOS ANGELES, Nov. 03, 2026 (GLOBE NEWSWIRE) — Cannabis Strategic Ventures, Inc. (OTC: NUGS) (“NUGS” or the “Company”) today announced that it signed a binding letter of intent (the “LOI”) with Scopien Technologies Inc. (“Scopien”), an Ontario corporation. Under the LOI, Scopien would acquire voting control of NUGS through the transfer of the Company’s Series B Super Voting Preferred Stock and contribute its operating business to the Company. The parties intend to complete the change of control by November 30, 2026.

Termination of Adport Letter of Intent

The Company also announced that it has terminated the non-binding letter of intent with Adport Inc. announced on September 10, 2026, under which the Company had proposed to acquire substantially all of Adport’s intellectual property and operating assets. No definitive agreements were entered into with Adport.

About the Scopien Platform

Scopien connects a company’s systems, including CRM, ERP, HR, payroll and helpdesk, into one operating platform and puts AI agents to work across it. Each customer runs its own instance in Scopien’s cloud, its own cloud or on-premises, so data stays inside its walls. Scopien serves mid-market companies, enterprises and government, and plans to expand its sales and partner channels, product modules and engineering program.

What Comes Next

When the change of control closes, Scopien would appoint NUGS’s officers and directors. The Company intends to change its name and trading symbol to reflect the Scopien business, subject to FINRA processing, and to complete PCAOB audits and file a registration statement with the SEC within six months following the change of control, with the goal of becoming a fully reporting company and pursuing a Nasdaq or NYSE listing.

“We rebuilt this company through the courts so shareholders would have something real to build on,” said Richard C. Hawkins, Chief Executive Officer of NUGS. “Scopien is the kind of company we hoped to find.”

“Every business should work as one,” said Zameer Mulla, Chief Executive Officer of Scopien. “Being a public company holds us to the standard of transparency our customers expect. Our first priority is completing the audit and the registration statement.”

Court Custodianship

In July 2025, the Eighth Judicial District Court of Nevada, Clark County, appointed a custodian for the Company, which at the time had no operations and carried more than $14.6 million in legacy liabilities. The custodian reinstated the Company, ran a court-supervised creditor-notice process and, in December 2025, obtained an order barring unasserted claims. In April 2026, the Court ratified the custodian’s actions and returned control to the board. Total reported liabilities were approximately $491,000 at September 30, 2026, and all legacy Series C Preferred Stock has been cancelled.

About Scopien Technologies Inc.

Scopien Technologies Inc., based in Oakville, Ontario, builds sovereign AI that makes every business work as one. For more information, visit www.scopien.com.

About Cannabis Strategic Ventures, Inc.

Cannabis Strategic Ventures, Inc. is a Nevada corporation quoted on OTC Markets under the symbol “NUGS.” Following a court-supervised custodianship completed in April 2026, the Company is pursuing business combinations with operating businesses that have growth potential.

Investor Contact

info@cannabisstrategic.ventures | +1 480-788-7420

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the proposed change of control, the contribution of Scopien’s business, the audit and registration statement, and potential exchange listing. These statements are subject to significant risks and uncertainties, including: that definitive agreements may not be executed or the LOI may be terminated; that the audit and registration statement may not be completed as contemplated; that Scopien’s business may not grow as anticipated; that additional funding may not be available; that securities remain subject to former-shell-company resale restrictions under Rule 144(i); that exchange listing standards may not be met; and that legacy indebtedness and future financing may substantially dilute common stockholders. The super-voting preferred stock would concentrate voting control in Scopien.

The safe harbor provided by Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 is not available to the Company. The Company undertakes no obligation to update any forward-looking statement except as required by law. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Source: Cannabis Strategic Ventures, Inc.